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Renal denervation in South Africa
To the Editor: Renal denervation (RD) is a minimally invasive 
therapy aimed primarily at hypertension.[1] The procedure involves 
modification of the renal sympathetic nerve supply, which courses 
around the renal arteries. Access to the renal arteries is obtained 
via peripheral vessels (femoral, radial or brachial artery), and 
radiofrequency energy is applied to the arterial wall.[2] After proof-
of-concept studies in animals and humans, the SYMPLICITY 
HTN-2 trial demonstrated a significant blood pressure reduction in 
patients with resistant hypertension, compared with pharmacological 
management.[3] Surprisingly, RD was not found to be more effective 
than a sham procedure for resistant hypertension in the SYMPLICITY 
HTN-3 trial.[4] This trial, however, was subject to significant 
limitations, including the inability to monitor treatment adherence 
and changes of pharmacotherapy during the trial, as well as variation 
in the extent of RD performed in individual patients. Three sham-
controlled trials have been published since, addressing many of the 
shortcomings of SYMPLICITY HTN-3. The SPYRAL-HTN-OFF 
MED trial[5] was designed to control for differences in between-
group pharmacotherapy, and blood pressure at 3 months’ follow-up 
was significantly lower in the RD group than in the sham procedure 
group. In the SPYRAL-HTN-ON MED trial,[6] pharmacotherapy 
was continued, and blood pressure control was also improved in 
RD recipients. In the endovascular ultrasound renal denervation to 
treat hypertension (RADIANCE-HTN SOLO) trial,[7] RD was more 
effective in decreasing blood pressure than a sham procedure.
The latter three trials have provided compelling new evidence for 
RD efficacy, with few major complications. By correcting for the 
confounders of the SYMPLICITY-HTN-3 trial, the SPYRAL-HTN-
OFF MED, SPYRAL HTN-ON MED and RADIANCE-HTN SOLO 
trials have provided substantial evidence in favour of RD, expanding 
its scope to patients who do not suffer from resistant hypertension. 
In preclinical and clinical models, RD has demonstrated benefits 
beyond blood pressure reduction, e.g. attenuation of adverse left 
ventricular remodelling and improvement in left ventricular systolic 
function, which have led to the investigation of RD for applications 
other than hypertension treatment, e.g. the prevention of atrial 
fibrillation.[8]
RD has not become widespread as a treatment option for 
hypertension in South Africa (SA). All RD therapy is currently 
provided in the private sector. The South African Heart Association 
and the Southern African Hypertension Society released a consensus 
statement regarding RD in 2014,[9] which recommends that it only 
be performed as part of prospective studies or registries. Although 
these recommendations were written before the SPYRAL-HTN-OFF 
MED, SPYRAL HTN-ON MED and RADIANCE-HTN SOLO trials 
were published, they allow for patients with resistant hypertension 
to be referred to centres of expertise for possible inclusion in a 
trial or a clinical registry. In a recent study of more than 10 000 
individuals in sub-Saharan Africa,[10] SA had the highest prevalence 
of hypertension, with a high degree of uncontrolled blood pressure 
(55.4% women, 68.1% men) in the study sites. Given the substantial 
healthcare burden of hypertension in SA and the latest evidence base, 
the time has come to review the local recommendations and allow 
RD technology to penetrate the SA healthcare system. This will only 
be achieved by a co-ordinated effort between healthcare providers, 
funders and regulators.
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